Researchers from Houston Methodist Sugar Land Hospital recently implanted the Crux® Vena Cava Filter in the first patient in Texas with a risk of pulmonary embolism (PE). PE is caused by a large blood clot stacking in the lung and the Crux® Vena Cava Filter is designed to catch blood clots preventing a fatal outcomes.
A 51-year-old male patient was brought to the emergency room with pain caused by a blood clot in his leg, and received implantation of the Crux® Vena Cava Filter and medication to break up the clot. Imran Mohiuddin, M.D., vascular surgeon and Uttam Tripathy, M.D., cardiothoracic surgeon, conducted the surgery. The filter will be removed out of the patient’s body when the clot is dissolved.
Crux® Vena Cava Filter is uniquely designed to be implanted in inferior vena cava (IVC) either in the neck or in the leg to trap a clot in the blood flow. The new device coul be an important tool for physicians to prevent recurrent PE and potential death on PE.
“We continuously strive to use the safest, most technically-advanced and effective devices and procedures to ensure the best outcomes for our patients,” said Mohiuddin.
A new wave of Vena Cava Filters have recently come to light in the biotech sector. BioNews Texas science columnist Maureen Neuman recently profiled a new Texas-based Vena Cava Filter design in an article back in January of 2014, after Plano, Texas-based Argon Medical announced that the Option(™)ELITE Retrievable Vena Cava Filter had received FDA Market Approval. The Crux Vena Cava Filter is designed and manufactured by San Diego-based Volcano Corporation, and employs a symmetrical spiral design that self-centers the filter automatically in the vessel lumen. The novel design of the Crux Vena Cava filter, which is seeing an increasing number of successful applications in patients nationwide, will give surgeons a new option in effectively treating serious conditions related to pulmonary embolism.